New SLEEP 2026 data show orexin agonist oveporexton boosts cognition, daily function, and reduces microsleeps in narcolepsy type 1.
Elena Koundourakis, PhD
Advertisement
Dr Koundourakis is head of the Orexin Franchise Development and Portfolio Strategy at Takeda.
Articles by Elena Koundourakis, PhD
New phase 3 data show oveporexton (TAK-861) boosts functioning and cognition, eases NT1 symptoms, and improves sleep
Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
Advertisement
Latest Updated Articles
The Role of Orexin Receptor 2 Agonists in Sleep and Narcolepsy Type 1February 15th 2024
Advertisement
Advertisement
Trending on Psychiatric Times
1
Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health
2
Seltorexant as Adjunctive Therapy for MDD With Insomnia
3
Psychiatric Comorbidities in Adults With Congenital Heart Disease and the Need for Interdisciplinary Care
4
Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder
5